Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy

Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy - Study of galectin-9 as novel biomarker of activity and therapeutic agent in IgA nephropathy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015551

Enrollment

Registered

2014-11-11

Start date

2014-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have been diagnosed with IgA nephropathy by renal biopsy Patients who will receive the tonsillectomy and steroid therapy. Patients who agree to participate in the study.

Exclusion criteria

Exclusion criteria: Patients under age 16 and over 80. Patients who do not agree to participate in the study. Patients decided by the doctor to be unsuitable to the study other than above.

Design outcomes

Primary

Measure	Time frame
Urinary protein, hematuria, serum creatinine, estimated GFR, histological findings	—

Countries

Japan

Contacts

Public ContactMasahiro Moritoki

Kagawa University Hospital Department of nephrology

moritoki@med.kagawa-u.ac.jp087-891-2149

Outcome results